Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer

被引：0
|
作者：
Gupta, Shilpa
Munster, Pamela N.
Hollebecque, Antoine
Argues, Guillem
Dajanl, Olav
Chang, Jonathan D.
Swift, Ann M.
Tosolini, Alessandra
Piha-Paul, Sarina Anne
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[3] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Merck & Co Inc, Whitehouse Stn, NJ USA
[7] Merck & Co Inc, N Wales, PA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2509
引用
收藏
页数：1
相关论文
共 49 条
  • [21] Cytotoxic t-lymphocyte density increased within the tumor immune microenvironment of patients with breast cancer following treatment with Akt inhibitor MK-2206
    Marks, Douglas K.
    Gartrell, Robyn D.
    Asmar, Margueritta E.
    Hart, Thomas D.
    Lu, Yan
    Esancy, Camden L.
    Hibshoosh, Hanina
    Connolly, Eileen P.
    Kalinsky, Kevin M.
    Saenger, Yvonne M.
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
    Wisinski, Kari B.
    Tevaarwerk, Amye J.
    Burkard, Mark E.
    Rampurwala, Murtuza
    Eickhoff, Jens
    Bell, Maria C.
    Kolesar, Jill M.
    Flynn, Christopher
    Liu, Glenn
    CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2659 - 2667
  • [23] A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
    Brana, I.
    Berger, R.
    Golan, T.
    Haluska, P.
    Edenfield, J.
    Fiorica, J.
    Stephenson, J.
    Martin, L. P.
    Westin, S.
    Hanjani, P.
    Jones, M. B.
    Almhanna, K.
    Wenham, R. M.
    Sullivan, D. M.
    Dalton, W. S.
    Gunchenko, A.
    Cheng, J. D.
    Siu, L. L.
    Gray, J. E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (10) : 1932 - 1944
  • [24] A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
    I Brana
    R Berger
    T Golan
    P Haluska
    J Edenfield
    J Fiorica
    J Stephenson
    L P Martin
    S Westin
    P Hanjani
    M B Jones
    K Almhanna
    R M Wenham
    D M Sullivan
    W S Dalton
    A Gunchenko
    J D Cheng
    L L Siu
    J E Gray
    British Journal of Cancer, 2014, 111 : 1932 - 1944
  • [25] A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma, Cynthia X.
    Sanchez, Cesar
    Gao, Feng
    Crowder, Robert
    Naughton, Michael
    Pluard, Timothy
    Creekmore, Allison
    Guo, Zhanfang
    Hoog, Jeremy
    Lockhart, A. Craig
    Doyle, Austin
    Erlichman, Charles
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2650 - 2658
  • [26] AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor
    Chen, Xiaoyu
    Cui, Danrui
    Bi, Yanli
    Shu, Jianfeng
    Xiong, Xiufang
    Zhao, Yongchao
    CELL CYCLE, 2018, 17 (16) : 2069 - 2079
  • [27] Combination of fulvestrant with the allosteric Akt inhibitor MK-2206 promotes anti-tumor activity in estrogen deprivation resistant estrogen receptor positive breast cancer
    Sanchez, Cesar G.
    Crowder, Robert J.
    Phommaly, Chanpheng
    Ellis, Matthew J.
    CANCER RESEARCH, 2011, 71
  • [28] Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor
    Vilquin, Paul
    Villedieu, Marie
    Grisard, Evelyne
    Ben Larbi, Sabrina
    Ghayad, Sandra E.
    Heudel, Pierre-Etienne
    Bachelot, Thomas
    Corbo, Laura
    Treilleux, Isabelle
    Vendrell, Julie A.
    Cohen, Pascale A.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (07) : 1589 - 1602
  • [29] Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.
    Yardley, D. A.
    Seiler, M.
    Ray-Coquard, I
    Melichar, B.
    Hart, L.
    Dieras, V
    Barve, M.
    Melnyk, A.
    Dorer, D.
    Turner, C. D.
    Dodion, P.
    CANCER RESEARCH, 2009, 69 (24) : 676S - 676S
  • [30] A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+breast cancer
    Nazeef, Moniba
    Tevaarwerk, Amye J.
    Eickhoff, Jens
    Burkard, Mark E.
    Heideman, Jennifer
    Liu, Glenn
    Flynn, Chris
    Kolesar, Jill M.
    Wisinski, Kari B.
    CANCER RESEARCH, 2015, 75
12345